AgomAb (AGMB) Director Garcia Marino Receives Option Award

What Happened
Garcia Marino, a director of AgomAb Therapeutics NV (AGMB), received a grant of derivative securities representing 57,482 shares on September 11, 2026. The transaction is reported as an award/acquisition (code A) with an acquisition price of $0.00 — i.e., an equity award/option was granted rather than a purchase. No immediate cash was paid and no shares were sold as part of this filing.

Key Details

• Transaction date: September 11, 2026; Form 4 filed September 15, 2026 (appears timely).
• Security: derivative (option) covering 57,482 common shares (may be represented by American Depositary Shares per footnote).
• Reported price: $0.00 (award/grant).
• Vesting: 33% vests on September 11, 2027; remaining shares vest in 24 equal monthly installments thereafter, subject to continued service (footnote F3).
• Currency note: exercise price reported in USD reflects conversion from EUR at €1 = $1.1616 as of Sept 10, 2026 (footnote F2).
• Shares owned after transaction: not specified in the provided excerpt.
• Filing accession: 0001104659-26-107916 (period of report: 2026-09-11).

Context
This filing reports a compensation-related equity award (an option/derivative), not an open-market buy or sale. Such grants are commonly used for director compensation and carry vesting conditions tied to continued service; they do not by themselves indicate an immediate change in share ownership or a decision to sell.